SERPANRAY
Clinical safety rating
cautionComprehensive clinical and safety monograph for SERPANRAY (SERPANRAY).
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6; minor pathways include CYP1A2 and CYP2C19. |
| Excretion | Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites. |
| Half-life | Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing. |
| Protein binding | 99.5% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd is 4.0 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Oral bioavailability is 30–40% due to first-pass metabolism. |
| Onset of Action | Oral: Clinical effects (antipsychotic) typically begin within 1–2 hours after first dose, with peak effects at steady state (10–14 days). |
| Duration of Action | After single oral dose, antipsychotic effects persist for 24 hours due to long half-life. Steady-state maintained with once-daily dosing. |
| Molecular Weight | 471.7 |
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min), use is not recommended due to lack of data. |
| Liver impairment | Child-Pugh Class A: No dosage adjustment. Child-Pugh Class B: Reduce dose to 1 mg once daily, may increase to 1.5 mg based on tolerability. Child-Pugh Class C: Use is not recommended. |
| Pediatric use | Not approved for pediatric patients below 18 years of age; no specific dosing guidelines available. |
| Geriatric use | Elderly patients may be more sensitive to sedative and orthostatic hypotensive effects. Initiate at 1 mg once daily, titrate cautiously. Maximum dose 1.5 mg once daily for patients >65 years. |
| 1st trimester | Insufficient human data; animal studies not available. Use only if potential benefit justifies risk. |
| 2nd trimester | Insufficient human data; animal studies not available. Use only if potential benefit justifies risk. |
| 3rd trimester | May cause extrapyramidal symptoms and/or withdrawal symptoms in neonates if used near term. Avoid use in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for SERPANRAY (SERPANRAY).
| Placental transfer | Placental transfer occurs; molecular weight suggests crossing. |
| Breastfeeding | Excreted in human milk; monitor infant for sedation and extrapyramidal symptoms. Use with caution, especially during neonatal period. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category N (not classified by FDA due to lack of data). |
| Fetal Monitoring | Monitor maternal vital signs, mental status, and extrapyramidal symptoms. Fetal monitoring per standard obstetrical care; no specific recommendations due to lack of data. |
| Fertility Effects | No human data on fertility effects. Animal studies not available. Theoretical risk of hyperprolactinemia and galactorrhea with antipsychotics; potential for transient menstrual irregularities. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SERPANRAY is not approved for the treatment of dementia-related psychosis.
| Serious Effects |
Hypersensitivity to itraconazole or any excipientConcurrent administration with CYP3A4 substrates known to prolong QT interval (e.g., pimozide, quinidine, levomethadyl, dronedarone, ranolazine, lurasidone)Concurrent use with HMG-CoA reductase inhibitors metabolized by CYP3A4 (e.g., simvastatin, lovastatin)Concurrent use with ergot alkaloids (e.g., ergotamine, dihydroergotamine)Concurrent use with irinotecanConcurrent use with colchicine in patients with renal or hepatic impairment
| Precautions | Cerebrovascular adverse events in elderly dementia patients; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); hyperprolactinemia; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; falls; cognitive and motor impairment; increased mortality in elderly with dementia. |
| Food/Dietary | Take with food to enhance absorption. High-fat meals increase lumateperone exposure. Avoid grapefruit juice as it may increase drug levels. |
| Clinical Pearls | SERPANRAY (lumateperone) is an atypical antipsychotic with a unique receptor binding profile (5-HT2A antagonist, D2 antagonist, and SERT inhibitor). It is indicated for schizophrenia and bipolar depression. Dosing is fixed at 42 mg once daily with food. No dose titration required. Common side effects include somnolence, sedation, and dry mouth. Monitor for metabolic changes, extrapyramidal symptoms, and tardive dyskinesia. Avoid use in hepatic impairment (Child-Pugh B or C). |
| Patient Advice | Take SERPANRAY exactly as prescribed once daily with food. · Do not stop taking this medicine without talking to your doctor. · This medicine may cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you. · Rise slowly from a sitting or lying position to minimize dizziness. · Inform your doctor immediately if you experience muscle stiffness, fever, confusion, or uneven heartbeat. · Avoid alcohol while taking SERPANRAY. |
Loading safety data…